HTS technologies in biopharmaceutical discovery

Drug Discovery Today

Volumn 11, Issue 15-16, 2006, Pages 718-724

  Wu, Ge ^a   Doberstein, Stephen K ^a  

^a FIVE PRIME THERAPEUTICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL SURFACE RECEPTOR; COMPLEMENTARY DNA; DIMETHYL SULFOXIDE; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN;

ABSORPTION SPECTROSCOPY; ANALYTICAL ERROR; BIOTECHNOLOGY; CLASSIFICATION; COMPARATIVE STUDY; DNA LIBRARY; DRUG IDENTIFICATION; DRUG TARGETING; ENZYME ASSAY; EXPRESSED SEQUENCE TAG; FLUORESCENCE POLARIZATION; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENCE SPECTROSCOPY; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENOME; IMMUNE SYSTEM; IMMUNOASSAY; LUMINESCENCE; MAMMAL CELL; MATHEMATICAL GENETICS; MEASUREMENT; MOLECULAR CLONING; MOLECULE; NONHUMAN; PHARMACOGENOMICS; PROCESS DEVELOPMENT; PROTEIN ANALYSIS; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROCESSING; PROTEIN TARGETING; QUANTITATIVE ANALYSIS; REVIEW; SCINTILLATION PROXIMITY ASSAY; SPECIES COMPARISON; THREE DIMENSIONAL IMAGING;

ANIMALS; BIOPHARMACEUTICS; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; DRUG INDUSTRY; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 33745862756     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drudis.2006.06.010     Document Type: Review

References (60)

1. Nagle T., et al. The further evolution of biotech. Nat. Rev. Drug Discov. 2 (2003) 75-79
2. Pavlou A.K., and Reichert J.M. Recombinant protein therapeutics success rates, market trends and values to 2010. Nat. Biotechnol. 22 (2004) 1513-1519
3. Brekke O.H., and Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat. Rev. Drug Discov. 2 (2003) 52-62
4. Walsh G. Current status of biopharmaceuticals: approved products and trends in approvals. In: Knablein J. (Ed). Modern biopharmeceuticals: design, development and optimization (2005), Wiley-VCH Verlag 1-34
5. Walsh G. Biopharmaceuticals: biochemistry and biotechnology. 2nd edn (2003), John Wiley & Sons
6. Ho R.J.Y., and Gibaldi M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs (2003), Wiley-Liss
7. Mitchell P. Next-generation monoclonals less profitable than trailblazers?. Nat. Biotechnol. 23 (2005) 906
8. Emilien G., et al. Impact of genomics on drug discovery and clinical medicine. QJM 93 (2000) 391-423
9. Jackson P.D., and Harrington J.J. High-throughput target discovery using cell-based genetics. Drug Discov. Today 10 (2005) 53-60
10. Hodges E., et al. Accelerated discovery of novel protein function in cultured human cells. Mol. Cell. Proteomics 4 (2005) 1319-1327
11. Harada J.N., et al. Identification of novel mammalian growth regulatory factors by genome-scale quantitative image analysis. Genome Res. 15 (2005) 1136-1144
12. Chanda S.K., et al. Genome-scale functional profiling of the mammalian AP-1 signaling pathway. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12153-12158
13. Clark H.F., et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 13 (2003) 2265-2270
14. Fiscella M., et al. TIP, a T-cell factor identified using high-throughput screening increases survival in a graft-versus-host disease model. Nat. Biotechnol. 21 (2003) 302-307
15. Janzen W.P. High throughput screening: methods and protocols (2002), Humana Press
16. Devlin J. High throughput screening (1997), CRC Press
17. Seethala R., and Fernandes P.B. Handbook of drug screening (2001), Marcel Dekker
18. Zhang J.-H., et al. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J. Biomol. Screen. 4 (1999) 67-73
19. Wu G., et al. Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J. Biomol. Screen. 8 (2003) 694-700
20. Fox S., et al. High-throughput screening: searching for higher productivity. J. Biomol. Screen. 9 (2004) 354-358
21. Chen C., et al. An integrated functional genomics screening program reveals a role for BMP-9 in glucose homeostasis. Nat. Biotechnol. 21 (2003) 294-301
22. Schneider G., and Fechner U. Computer-based de novo design of drug-like molecules. Nat. Rev. Drug Discov. 4 (2005) 649-663
23. ENCODE Project Consortium. The ENCODE (ENCyclopedia Of DNA Elements) project. Science 306 (2004) 636-640
24. Imanishi T., et al. Integrative annotation of 21,037 human genes validated by full-length cDNA clones. PLoS Biol. 2 (2004) e162
25. Brent M.R. Genome annotation past, present, and future: How to define an ORF at each locus. Genome Res. 15 (2005) 1777-1786
26. The FANTOM Consortium. The transcriptional landscape of the Mamm. Genome. Science 309 (2005) 1559-1563
27. Konno H., et al. Computer-based methods for the mouse full-length cDNA encyclopedia: real-time sequence clustering for construction of a nonredundant cDNA library. Genome Res. 11 (2001) 281-289
28. Pruitt K.D., and Maglott D.R. RefSeq and LocusLink: NCBI gene-centered resources. Nucleic Acids Res. 29 (2001) 137-140
29. The MGC Project Team. The status, quality, and expansion of the NIH full-length cDNA project: the mammalian gene collection (MGC). Genome Res. 14 (2004) 2121-2127
30. Carninci P., et al. Thermostabilization and thermoactivation of thermolabile enzymes by trehalose and its application for the synthesis of full length cDNA. Proc. Natl. Acad. Sci. U. S. A. 95 (1998) 520-524
31. Carninci P., et al. Normalization and subtraction of cap-trapper-selected cDNAs to prepare full-length cDNA libraries for rapid discovery of new genes. Genome Res. 10 (2000) 1617-1630
32. Carninci P., et al. Targeting a complex transcriptome: the construction of the mouse full-length cDNA encyclopedia. Genome Res. 13 (2003) 1273-1289
33. Carninci P., et al. High efficiency selection of full-length cDNA by improved biotinylated cap trapper. DNA Res. 4 (1997) 61-66
34. Nielsen H., et al. A neural network method for identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. Int. J. Neural Syst. 8 (1997) 581-599
35. Chen Y., et al. SPD - a web-based secreted protein database. Nucleic Acids Res. 33 (2005) D169-D173
36. Klee E.W., et al. Identifying secretomes in people, pufferfish and pigs. Nucleic Acids Res. 32 (2004) 1414-1421
37. Zhang Z., and Henzel W.J. Signal peptide prediction based on analysis of experimentally verified cleavage sites. Protein Sci. 13 (2004) 2819-2824
38. Hofmann K., and Stoffel W. TMBASE - a database of membrane spanning protein segments. Biol. Chem. Hoppe-Seyler 374 (1993) 166
39. Bateman A., et al. The Pfam protein families database. Nucleic Acids Res. 32 (2004) D138-D141
40. Revest J.-M., et al. Fibroblast growth factor 9 secretion is mediated by a non-cleaved amino-terminal signal sequence. J. Biol. Chem. 275 (2000) 8083-8090
41. Gewurz B.E., et al. US2, a human cytomegalovirus-encoded type I membrane protein, contains a non-cleavable amino-terminal signal peptide. J. Biol. Chem. 277 (2002) 11306-11313
42. Miyakawa K., and Imamura T. Secretion of FGF-16 requires an uncleaved bipartite signal sequence. J. Biol. Chem. 278 (2003) 35718-35724
43. Bendtsen J.D., et al. Feature-based prediction of non-classical and leaderless protein secretion. Protein Eng. Des. Sel. 17 (2004) 349-356
44. Fukuhara A., et al. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin. Science 307 (2005) 426-430
45. Goldstein A.L., et al. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends Mol. Med. 11 (2005) 421-429
46. Acton T.B., et al. Robotic cloning and protein production platform of the northeast structural genomics consortium. Methods Enzymol. 394 (2005) 210-243
47. Vincentelli R., et al. Automated expression and solubility screening of His-tagged proteins in 96-well format. Anal. Biochem. 346 (2005) 77-84
48. Wurm F.M. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat. Biotechnol. 22 (2004) 1393-1398
49. Walters W.P., and Namchuk M. Designing screens: how to make your hits a hit. Nat. Rev. Drug Discov. 2 (2003) 259-266
50. Iourgenko V., et al. Identification of a family of cAMP response element-binding protein coactivators by genome-scale functional analysis in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 12147-12152
51. Kunz-Schughart L.A., et al. The use of 3-D cultures for high-throughput screening: the multicellular spheroid model. J. Biomol. Screen. 9 (2004) 273-285
52. Giuliano K.A., et al. High-content screening: a new approach to easing key bottlenecks in the drug discovery process. J. Biomol. Screen. 2 (1997) 249-259
53. Comley J. Label-free detection. Drug Discovery World 6 (2005) 63-74
54. Ciambrone G.J., et al. Cellular dielectric spectroscopy: a powerful new approach to label-free cellular analysis. J. Biomol. Screen. 9 (2004) 467-480
55. Cunningham B.T., et al. Label-free assays on the bind system. J. Biomol. Screen. 9 (2004) 481-490
56. Dove A. Drug Screening-beyond the bottleneck. Nat. Biotechnol. 17 (1999) 859-863
57. Mullin R. Drug Discovery: As high-throughput draws fire, researchers leverages science to put automation into perspective. C&EN 26 (2004) 23-32
58. Molloy C. The industrial evolution of screening infrastructure. Drug Discovery World 4 (2003) 23-32
59. Ladd B. Intuitive data analysis: the next generation. Modern Drug Discovery 3 (2000) 46-51
60. Sun D., et al. Adopting a practical statistical approach for evaluating assay agreement in drug discovery. J. Biomol. Screen. 10 (2005) 508-516